Join us for an insightful interview with Professor Saskia Middeldorp from Radboud University Medical Center in Nijmegen, The Netherlands, as she and our host Dr. Isabel Olivera-Martinez, discuss the medical and ethical challenges of conducting randomized clinical trials to prevent venous thromboembolism (VTE) during pregnancy.

VTE is a leading cause of maternal morbidity and mortality, and poses significant risks to pregnant women. Together, explore the relevance of prophylactic treatments like low molecular weight heparin, and the ethical and financial complexities of conducting trials in this population. Learn about the ALIFE2 trial results, that assessed whether LMWH heparin should be used in women with recurrent miscarriage and inherited thrombophilia; well as the latest research and guidelines aimed at improving care for pregnant women at risk of VTE.

Host: Isabel Olivera-Martinez, PhD, Medical Writer

Guest: Prof Saskia Middeldorp

If you liked this podcast and would like to explore related content, you can check out our clinical case about Thrombosis and Hemostasis on the EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for an insightful interview with Professor Frank Leebeek from Erasmus University in Rotterdam, The Netherlands, as he discusses together with our host, Dr. Isabel Olivera-Martinez, the potential of gene therapy to free hemophilia patients from the standard coagulation factor replacement therapy.

Prof. Leebeek explains how gene therapy for hemophilia is carried out and differentiates the current possibilities for hemophilia A patients versus those with hemophilia B. He also highlights the advantages and challenges of this life-changing therapy, including its long-term effects, while addressing patient concerns related to safety and accessibility. Finally, he provides a glimpse into the future of gene therapy.

Host: Isabel Olivera-Martinez, PhD, Medical Writer

Guest: Prof Frank Leebeek

If you liked this podcast and would like to explore related content, you can check out our EHA Gene Therapy Techniques Program on the EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

In this podcast episode, we will explore the application of artificial intelligence to morphological diagnosis in hematology. Listening to our host, Dr Mahesh Prahladan (University of Suffolk, UK) you will learn how innovative machine learning and deep learning models have led to the development of AI systems that have been applied in various areas of hematology, including digital pathology.

As these systems have shown promise in improving diagnostic accuracy and efficiency, they also have a potential for enlarging accessibility to precise diagnostics, through remote digital morphology, and have potential applications in the prognostic stratification of patients.

According to Dr Prahladan, we are not ready to dispose of our microscopes yet, but automation may become a useful and time-saving tool in the hands of morphologists.

Host: Dr Enrica Orsini

Guest: Dr Mahesh Prahladan

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain), the first academic centre to achieve the authorisation to treat patients with a CAR T therapy developed 100% by academia.

Prof Delgado discusses the complexities of obtaining regulatory approval for CAR T-cell therapy, under the EU regulation for advanced therapy medicinal products (ATMPs).

In this episode, Prof Delgado shares his own experience learning to navigate the EU regulatory expectations while working at the European Medicines Agency (EMA). He emphasizes the importance of scientists understanding these regulations and regulators understanding the specific position of academia in the approval pathway for ATMPs. Listen and take advantage of his valuable insights!

Host: Isabel Olivera-Martinez, Medical Writer

Guest: Prof Julio Delgado

This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for this podcast discussing the promises and challenges of academic and point-of-care CAR T-cell manufacturing with Dr Anna Sureda, president of EBMT (European Society for Blood and Marrow Transplantation).

Dr Sureda provides her expert point of view on how CAR T-cells produced in academic centres may enhance patient access to CAR-T treatment, reducing costs and turnround times for production, and on the regulatory and quality issues linked to decentralized manufacturing of CAR T-cells.

Discover the current European landscape for academic CAR-T production, the evidence and experiences accumulated so far, and the potential role of scientific societies such as EBMT and EHA in shaping the future of CAR-T treatment.

Host: Enrica Orsini

Guest: Dr Anna Sureda

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain) as he explains the intricate process of CAR T-cell therapy. In this episode, we cover the key steps involved in CAR T, such as patient identification, apheresis, manufacturing, cell infusion and managing post-infusion related toxicities.

Prof Delgado offers expert insights on each component of this complex treatment and discusses possible improvements. He also highlights efforts to shorten vein-to-vein time and the importance of academic and non-profit manufacturing in reducing costs. This conversation offers a solid overview for clinicians and hematologists interested in advanced therapy medicinal products (ATMPs).

Host: Isabel Olivera-Martinez, Medical Writer

Guest: Prof Julio Delgado

This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Tune in to our podcast for an in-depth discussion on CAR T-cell therapy for acute lymphocytic leukemia (ALL) in children. In this episode, we feature Professor Concetta Quintarelli, a renowned expert in hematology from the Bambino Gesù Children Hospital in Rome.

With host Isabel Olivera, they explore the advancements and challenges in treating ALL with CAR T-cells, the balance between treatment efficacy and safety, and the potential of combining CAR T-cells with other immunotherapies. The episode also delves into the complexities of the tumor microenvironment in ALL, antigen selection for targeted therapy, and the design of smarter CAR T-cells.

Professor Quintarelli discusses the future of CAR T-cell therapy, including the role of natural killer cells in ALL treatment and the importance of early intervention. Don't miss this insightful conversation on the latest developments in CAR T therapy for pediatric patients.

Host: Dr Isabel Olivera

Guest: Prof Concetta Quintarelli

This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe

Tune in to our podcast for an in-depth discussion on immunotherapeutic strategies for Acute Myeloid Leukemia (AML). In this episode, we feature Dr Sarah Tettamanti, a senior scientist at the Fondazione Tettamanti Research Centre in Italy, who shares her expertise on CAR T-cell therapy for AML.

With host Dr Sarah de Vlieger, they examine the progress and challenges in treating AML with CAR T-cells, the balance between treatment efficacy and safety, and the potential of combining CAR T-cells with other immunotherapies.

The episode also covers the complexities of the tumor microenvironment in AML, antigen selection for targeted therapy, and the design of smarter CAR T-cells. Sarah discusses the future of CAR T-cell therapy, including fourth-generation CAR T-cells and the role of natural killer cells in AML treatment.

Host: Dr Sarah de Vlieger

Guest: Dr Sarah Tettamanti

This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!

Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.

What did you think of this podcast? Share your opinions with us in this short feedback survey.

Provide Feedback

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

https://ehaedu.org/Campus

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/

Facebook: https://e-h-a.link/facebook

LinkedIn: https://www.linkedin.com/company/eha/

Email us: education@ehaweb.org

Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe